S0502 Follow Up Form S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Source Form: NCI FormBuilder:


Versions (2) ▾
  1. 9/19/12
  2. 1/9/15
Uploaded on:

January 9, 2015

No DOI assigned. To request one please log in.
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Gastrointestinal Stromal Tumor NCT00324987 Follow-Up - S0502 Follow Up Form - 2321009v1.0

No Instruction available.

  1. StudyEvent: S0502 Follow Up Form
    1. No Instruction available.
Vital Status
Vital Status
Has the patient had a documented clinical assessment for this cancer (since submission of the previous follow-up form)
Has the patient developed a first relapse or progression that has not been previously reported
Has a new primary cancer or MDS been diagnosed that has not been previously reported? (myelodysplastic syndrome)
Has the patient received any non-protocol cancer therapy (prior to progression/relapse) not previously reported?
Type of Therapy
Has the patient experienced any severe long term toxicity that has not been previously reported? (prior to treatment for progression or relapse or a second primary, and prior to non-protocol treatment grade >=3)

Similar models